Crossmark

Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland

Crossref DOI link: https://doi.org/10.1136/rmdopen-2020-001174

Published Online: 2020-05-07

Published Print: 2020-05

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Finckh, A

Tellenbach, C

Herzog, L

Scherer, A

Moeller, B

Ciurea, A

von Muehlenen, I

Gabay, C

Kyburz, D

Brulhart, L

Müller, R

Hasler, P

Zufferey, P
License Information

Version of Record valid from 2020-04-10